501 related articles for article (PubMed ID: 33067472)
1. Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19.
Carissimo G; Xu W; Kwok I; Abdad MY; Chan YH; Fong SW; Puan KJ; Lee CY; Yeo NK; Amrun SN; Chee RS; How W; Chan S; Fan BE; Andiappan AK; Lee B; Rötzschke O; Young BE; Leo YS; Lye DC; Renia L; Ng LG; Larbi A; Ng LF
Nat Commun; 2020 Oct; 11(1):5243. PubMed ID: 33067472
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.
Liu J; Li S; Liu J; Liang B; Wang X; Wang H; Li W; Tong Q; Yi J; Zhao L; Xiong L; Guo C; Tian J; Luo J; Yao J; Pang R; Shen H; Peng C; Liu T; Zhang Q; Wu J; Xu L; Lu S; Wang B; Weng Z; Han C; Zhu H; Zhou R; Zhou H; Chen X; Ye P; Zhu B; Wang L; Zhou W; He S; He Y; Jie S; Wei P; Zhang J; Lu Y; Wang W; Zhang L; Li L; Zhou F; Wang J; Dittmer U; Lu M; Hu Y; Yang D; Zheng X
EBioMedicine; 2020 May; 55():102763. PubMed ID: 32361250
[TBL] [Abstract][Full Text] [Related]
3. Clinical Characteristics and Immune Injury Mechanisms in 71 Patients with COVID-19.
Wu Y; Huang X; Sun J; Xie T; Lei Y; Muhammad J; Li X; Zeng X; Zhou F; Qin H; Shao L; Zhang Q
mSphere; 2020 Jul; 5(4):. PubMed ID: 32669467
[TBL] [Abstract][Full Text] [Related]
4. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
Front Immunol; 2020; 11():581338. PubMed ID: 33123167
[TBL] [Abstract][Full Text] [Related]
5. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.
Hou H; Zhang B; Huang H; Luo Y; Wu S; Tang G; Liu W; Mao L; Mao L; Wang F; Sun Z
Clin Exp Immunol; 2020 Jul; 201(1):76-84. PubMed ID: 32365221
[TBL] [Abstract][Full Text] [Related]
6. Immune characteristics distinguish patients with severe disease associated with SARS-CoV-2.
Li X; Liu Y; Li J; Sun L; Yang J; Xu F; Zhou J; Wan L; Xu X; Le A; Zhang W
Immunol Res; 2020 Dec; 68(6):398-404. PubMed ID: 32989677
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-to-Lymphocyte Ratios Are Closely Associated With the Severity and Course of Non-mild COVID-19.
Qun S; Wang Y; Chen J; Huang X; Guo H; Lu Z; Wang J; Zheng C; Ma Y; Zhu Y; Xia D; Wang Y; He H; Wang Y; Fei M; Yin Y; Zheng M; Xu Y; Ge W; Hu F; Zhou J
Front Immunol; 2020; 11():2160. PubMed ID: 32983180
[TBL] [Abstract][Full Text] [Related]
8. Immune dysfunction following COVID-19, especially in severe patients.
Song CY; Xu J; He JQ; Lu YQ
Sci Rep; 2020 Sep; 10(1):15838. PubMed ID: 32985562
[TBL] [Abstract][Full Text] [Related]
9. Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients.
Urra JM; Cabrera CM; Porras L; Ródenas I
Clin Immunol; 2020 Aug; 217():108486. PubMed ID: 32479985
[TBL] [Abstract][Full Text] [Related]
10. Immune Parameters and COVID-19 Infection - Associations With Clinical Severity and Disease Prognosis.
Jesenak M; Brndiarova M; Urbancikova I; Rennerova Z; Vojtkova J; Bobcakova A; Ostro R; Banovcin P
Front Cell Infect Microbiol; 2020; 10():364. PubMed ID: 32695683
[TBL] [Abstract][Full Text] [Related]
11. Optimizing Administration of CAR T-Cell Therapy During the COVID-19 Pandemic.
Bishop MR
Clin Adv Hematol Oncol; 2020 Jul; 18(7):400-403. PubMed ID: 32903251
[No Abstract] [Full Text] [Related]
12. Immune characteristics of severe and critical COVID-19 patients.
Yang L; Gou J; Gao J; Huang L; Zhu Z; Ji S; Liu H; Xing L; Yao M; Zhang Y
Signal Transduct Target Ther; 2020 Aug; 5(1):179. PubMed ID: 32868756
[No Abstract] [Full Text] [Related]
13. Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm.
Mahmoudi S; Rezaei M; Mansouri N; Marjani M; Mansouri D
J Clin Immunol; 2020 Oct; 40(7):974-976. PubMed ID: 32648027
[No Abstract] [Full Text] [Related]
14. SARS-CoV-2 infection-induced immune responses: Friends or foes?
Li K; Hao Z; Zhao X; Du J; Zhou Y
Scand J Immunol; 2020 Aug; 92(2):e12895. PubMed ID: 32445403
[TBL] [Abstract][Full Text] [Related]
15. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia.
De Biasi S; Meschiari M; Gibellini L; Bellinazzi C; Borella R; Fidanza L; Gozzi L; Iannone A; Lo Tartaro D; Mattioli M; Paolini A; Menozzi M; Milić J; Franceschi G; Fantini R; Tonelli R; Sita M; Sarti M; Trenti T; Brugioni L; Cicchetti L; Facchinetti F; Pietrangelo A; Clini E; Girardis M; Guaraldi G; Mussini C; Cossarizza A
Nat Commun; 2020 Jul; 11(1):3434. PubMed ID: 32632085
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil-to-Lymphocyte ratio as a potential biomarker for disease severity in COVID-19 patients.
Haghjooy Javanmard S; Vaseghi G; Manteghinejad A; Nasirian M
J Glob Antimicrob Resist; 2020 Sep; 22():862-863. PubMed ID: 32810639
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease.
Costela-Ruiz VJ; Illescas-Montes R; Puerta-Puerta JM; Ruiz C; Melguizo-Rodríguez L
Cytokine Growth Factor Rev; 2020 Aug; 54():62-75. PubMed ID: 32513566
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive mapping of immune perturbations associated with severe COVID-19.
Kuri-Cervantes L; Pampena MB; Meng W; Rosenfeld AM; Ittner CAG; Weisman AR; Agyekum RS; Mathew D; Baxter AE; Vella LA; Kuthuru O; Apostolidis SA; Bershaw L; Dougherty J; Greenplate AR; Pattekar A; Kim J; Han N; Gouma S; Weirick ME; Arevalo CP; Bolton MJ; Goodwin EC; Anderson EM; Hensley SE; Jones TK; Mangalmurti NS; Luning Prak ET; Wherry EJ; Meyer NJ; Betts MR
Sci Immunol; 2020 Jul; 5(49):. PubMed ID: 32669287
[TBL] [Abstract][Full Text] [Related]
19. Reappearance of effector T cells is associated with recovery from COVID-19.
Odak I; Barros-Martins J; Bošnjak B; Stahl K; David S; Wiesner O; Busch M; Hoeper MM; Pink I; Welte T; Cornberg M; Stoll M; Goudeva L; Blasczyk R; Ganser A; Prinz I; Förster R; Koenecke C; Schultze-Florey CR
EBioMedicine; 2020 Jul; 57():102885. PubMed ID: 32650275
[TBL] [Abstract][Full Text] [Related]
20. IL-6-based mortality risk model for hospitalized patients with COVID-19.
Laguna-Goya R; Utrero-Rico A; Talayero P; Lasa-Lazaro M; Ramirez-Fernandez A; Naranjo L; Segura-Tudela A; Cabrera-Marante O; Rodriguez de Frias E; Garcia-Garcia R; Fernández-Ruiz M; Aguado JM; Martinez-Lopez J; Lopez EA; Catalan M; Serrano A; Paz-Artal E
J Allergy Clin Immunol; 2020 Oct; 146(4):799-807.e9. PubMed ID: 32710975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
